JPMorgan analyst Chris Schott says his positive longer term thesis is unchanged following Mylan's investor day. Commentary on the near-term pipeline remained upbeat and Mylan highlighted multiple long-term revenue drivers, Schott tells investors in a research note. He believes the company's "significant" generic Advair opportunity, as well as other potential near-term approvals, more than offset any downside risk from ongoing challenges in the U.S. generics market. The analyst thinks Mylan shares remain "highly inexpensive." Schott keeps an Overweight rating on the name with a $53 price target.